Literature DB >> 18423106

Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.

Clare McCormick1, Armando Caballero, Aihua Tang, Charles Balzli, Jenny Song, Richard O'Callaghan.   

Abstract

OBJECTIVE: To quantitatively determine, in a Pseudomonas keratitis model, the anti-inflammatory and bactericidal properties of a new formulation of tobramycin (0.3%) and dexamethasone (0.05%) that utilizes a xanthan gum vehicle. RESEARCH
METHODS: In a randomized and masked fashion, rabbit corneas (n>/=16 eyes per group) were intrastromally injected with 10(3) colony-forming units (CFU) of P. aeruginosa. Eyes were untreated or were administered a single drop every 15 min between 16 and 17 h postinfection (PI) and then a single drop every 30 min between 17 and 22 h PI, a total of 15 drops of either 0.1% dexamethasone and 0.3% tobramycin (TobraDex; Tdex) or a new formulation 0.3% tobramycin and 0.05% dexamethasone with xanthan gum (TobraDex ST; ST). Slit lamp examination scores (SLE+/-SEM) were derived from grading seven parameters at 22 h PI. Rabbits were sacrificed at 23 h PI and the log CFU+/-SEM per cornea was determined.
RESULTS: Untreated eyes had SLE scores of 11.11+/-0.43 and had log CFU of 7.27+/-0.06. Eyes treated with Tdex, as compared to the untreated eyes, had significantly lower SLE scores (7.39+/-0.21, p<0.0001) and significantly fewer bacteria (6.32+/-0.29 log CFU, p=0.0213). Eyes treated with ST had a SLE score (6.56+/-0.19) that was significantly lower than both the untreated eyes (p<0.0001) and the eyes treated with Tdex (p=0.0124). Furthermore, eyes treated with ST had significantly fewer log CFU (5.78+/-0.30) than untreated eyes (p=0.0001) or eyes treated with Tdex (p=0.0434).
CONCLUSIONS: The ST formulation with xanthan gum demonstrated statistically superior anti-inflammatory and bactericidal properties as compared to Tdex. LIMITATIONS: Variations in inoculation procedures produced limited eye-to-eye differences in the infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423106     DOI: 10.1185/03007990802079877

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Innovative Cold Atmospheric Plasma (iCAP) Decreases Mucopurulent Corneal Ulcer Formation and Edema and Reduces Bacterial Load in Pseudomonas Keratitis.

Authors:  Wahaj Saleem; Angela H Benton; Mary E Marquart; Shuli Wang; Waqas Saleem; Randy Vigil; Bo Huang; Anjal C Sharma
Journal:  Clin Plasma Med       Date:  2019-12-27

Review 2.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

3.  Therapeutic possibilities of ceftazidime nanoparticles in devastating pseudomonas ophthalmic infections; keratitis and endophthalmitis.

Authors:  Mehrdad Mohammadpour; Mahmood Jabbarvand; Nasser Karimi
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2012

4.  Clinical and Antibacterial Effects of Tualang Honey on Pseudomonas-induced Keratitis in Rabbit Eyes.

Authors:  Rajendran Punitan; Siti Amrah Sulaiman; Habsah B Hasan; Ismail Shatriah
Journal:  Cureus       Date:  2019-03-27

5.  Determination of tobramycin in eye drops with an open-source hardware ion mobility spectrometer.

Authors:  Nattapong Chantipmanee; Peter C Hauser
Journal:  Anal Bioanal Chem       Date:  2022-04-05       Impact factor: 4.478

6.  Degradable and Non-Degradable Chondroitin Sulfate Particles with the Controlled Antibiotic Release for Bacterial Infections.

Authors:  Selin S Suner; Mehtap Sahiner; Ramesh S Ayyala; Nurettin Sahiner
Journal:  Pharmaceutics       Date:  2022-08-20       Impact factor: 6.525

7.  Management and treatment of contact lens-related Pseudomonas keratitis.

Authors:  Mark Dp Willcox
Journal:  Clin Ophthalmol       Date:  2012-06-18

8.  Wnt3a suppresses Pseudomonas aeruginosa-induced inflammation and promotes bacterial killing in macrophages.

Authors:  Kang Chen; Qiang Fu; Dandan Li; Yongjian Wu; Shijun Sun; Xiumin Zhang
Journal:  Mol Med Rep       Date:  2016-02-05       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.